Last reviewed · How we verify
NCT05940740
Investigation of the Effect of Training on the Side Effects of Chemotherapy Given Via the Mobile Health Application on the Quality of Life in Colorectal Cancer Patients
NA trial testing Colorectal-Mobile application in Colorectal Cancer in 70 participants. Completed in 14 January 2025.
1 March 2024
Quick facts
| Lead sponsor | NESLISAH YASAR KARTAL |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 70 |
| Start date | 1 March 2023 |
| Primary completion | 1 March 2024 |
| Estimated completion | 14 January 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Colorectal-Mobile application
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Mobile Phone Use — all drugs for Mobile Phone Use →
- Nurse's Role — all drugs for Nurse's Role →
Sponsor
NESLISAH YASAR KARTAL
Who can join
Adults 18 to 65, any sex, with Colorectal Cancer or Mobile Phone Use. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The incidence of colorectal cancer ranks fourth worldwide after lung, prostate and breast cancers. Although chemotherapy has an important place in the treatment of colorectal cancers, it can cause side effects such as diarrhea and fatigue in patients. Cancer patients' ability to cope with treatment side effects can be benefited from technological developments. Studies have shown that mobile health applications reduce symptom experience and increase quality of life in patients with breast cancer and leukemia.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effect of mobile health application-based training on chemotherapy side effects and quality of life in colorectal cancer patients: a randomized controlled trial
Kartal NY, Eroglu SA. · · 2026 · DOI 10.21203/rs.3.rs-9077015/v1
Verify or expand the search:
- PubMed search for NCT05940740
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05940740 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NESLISAH YASAR KARTAL
- Last refreshed: 14 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05940740.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing